An AI tool using echocardiograms accurately screens for cardiac amyloidosis, outperforming traditional detection methods.
Key Details
- 1AI model analyzes echocardiogram (ultrasound) images to screen for cardiac amyloidosis.
- 2Developed by Mayo Clinic and Ultromics; validated in a global, multi-ethnic cohort across 18 hospitals.
- 3Achieved 85% sensitivity and 93% specificity in detecting or ruling out cardiac amyloidosis.
- 4Outperformed existing clinical scoring systems for early diagnosis.
- 5FDA-cleared and already being implemented in multiple US hospitals.
Why It Matters
Early, accurate identification of cardiac amyloidosis is critical due to effective therapies available only at earlier disease stages. AI-based screening of routine cardiac ultrasound could substantially improve detection rates and patient outcomes, supporting broader integration of imaging AI in clinical care.
Source
EurekAlert
Related News
•EurekAlert
Optical AI Chip Boosts Real-Time Dry Eye Gland Diagnosis Accuracy
A new metasurface spectral AI chip enables rapid, accurate diagnosis of meibomian gland dysfunction (MGD) from tissue samples, achieving 96.22% accuracy.
•EurekAlert
New AI Vision-Language Model Enhances Chest CT Diagnostics
Researchers developed an interpretable AI model that uses visual question answering to generate detailed diagnostic findings from chest CT scans, aimed at improving lung cancer diagnosis.
•EurekAlert
AI Analyzes 66,000 MRI Scans to Map Body Composition Risks
Researchers used AI to analyze over 66,000 whole-body MRI scans, creating a detailed body composition reference map linked to health risks.